Management of Brain Metastases in Non-Small-Cell Lung Cancer

Area of Science:

• Oncology
• Neurology
• Pharmacology

Background:

• Lung cancer is a leading cause of cancer death, with brain metastases (BMs) occurring in approximately 20% of patients.
• Traditional treatments for NSCLC with BMs include surgery, stereotactic radiosurgery, and whole-brain radiation therapy.
• The advent of targeted therapies has complicated and advanced treatment strategies for BMs.

Purpose of the Study:

• To review current data on the management of non-small-cell lung cancer (NSCLC) with brain metastases (BMs).
• To discuss the evolving role of tyrosine kinase inhibitors (TKIs) and immunotherapy in treating CNS metastases from NSCLC.
• To outline an approach for managing NSCLC patients with BMs.

Main Methods:

• Review of current literature and clinical data.
• Analysis of the efficacy of tyrosine kinase inhibitors (TKIs) against central nervous system (CNS) metastases.
• Evaluation of the emerging role of immune checkpoint inhibitors in NSCLC with BMs.

Main Results:

• Many TKIs demonstrate significant and lasting efficacy against CNS metastases, often deferring the need for local therapy.
• TKIs can reduce the risk of CNS progression in patients with NSCLC.
• The role of immunotherapy in NSCLC with BMs is under active investigation.

Conclusions:

• Tyrosine kinase inhibitors represent a significant advancement in treating non-small-cell lung cancer brain metastases.
• Further research is needed to define the optimal role of immunotherapy in this patient population.
• A multidisciplinary approach is essential for managing NSCLC patients with BMs.